CoChat
Sign Up
Cited by 492Monoclonal and Polyclonal Antibodies ResearchT-cell and B-cell ImmunologyImmunotherapy and Immune Responses

Hybrid antibodies can target sites for attack by T cells

Staerz, Uwe D., Kanagawa, Osami, Bevan, Michael J.·1985·Nature
DOI 10.1038/314628a0
Open this paper in CoChat — free account

Abstract

It would be advantageous in the case of certain diseases to be able to focus a strong T-cell response at a chosen target, for example, in treating cancer or infections that have escaped the normal host response. At present, it seems inconceivable that we could use antigen-specific lines or clones of effector T cells for this purpose because of complications due to the major histocompatibility restriction of T-cell specificity and the problem of rejection of transplanted effector cells. Here we describe a novel technology which combines the power of T lymphocytes in eliminating unwanted cells and causing beneficial inflammatory reactions with the great advantages of monoclonal antibodies (their specificity and availability). We show that heteroconjugates of monoclonal antibodies (referred to hereafter as hybrid antibodies), in which one of the component binding sites is anti-T-cell receptor and the other component binding site is directed against any chosen target antigen, can focus T cells to act at the targeted site. Monoclonal antibodies directed against the T-cell receptor, such as the anti-allotype used here, are mitogenic for resting T cells and can be used to induce effector T cells carrying the T-cell receptor determinant which can then be directed against the target by a hybrid antibody.

Integrity signals

Registry

Crossref · 10.1038/314628a0

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Many monoclonal antibody shortcomings could be overcome by creating bispecific antibodies capable of simultaneous binding to two different targets.

    “many mAb shortcomings could be overcome by creating bispecific antibodies (bsAbs) capable of simultaneous binding to two different targets.”

    From Bispecific antibodies for cancer therapy: The light at the end of the tunnel? (2009) · cites this paper as [3]

  • The potential of using bispecific antibodies to retarget effector cells toward tumor cells was demonstrated in the 1980s.

    “The potential of using bispecific antibodies to retarget effector cells toward tumor cells was demonstrated in the 1980s 3,6,7”

    From Bispecific antibodies for cancer therapy: The light at the end of the tunnel? (2009) · cites this paper as [3]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Staerz, U. D., Kanagawa, O., & Bevan, M. J.
Affiliations
Scripps Clinic (US)
ORCID
Venue
Nature
Publisher
Springer Science and Business Media LLC
Published
1985-04
Volume
314
Issue
6012
Pages
628-631
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
DOI
10.1038/314628a0
OpenAlex
W2053104174
Cited by
492
References
15
Citations by year
2026: 12 · 2025: 8 · 2024: 17 · 2023: 18 · 2022: 14 · 2021: 18 · 2020: 16 · 2019: 13 · 2018: 19 · 2017: 13 · 2016: 13 · 2015: 13 · 2014: 13 · 2013: 7 · 2012: 16
FWCI
29.75
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Nature (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Cancer Institute (CA-25803)
  • National Institute of Allergy and Infectious Diseases (AI-19335)
Topics
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
hybrid antibodies, T cell receptor, monoclonal antibodies, T cell-mediated killing, T cell activation, effector T cells, targeted immunotherapy, cancer immunotherapy, MHC restriction
MeSH terms
Animals, Antibodies, Monoclonal, Antigens, Neoplasm, Antigens, Surface, Cytotoxicity, Immunologic, Immunity, Cellular, Receptors, Antigen, T-Cell, T-Lymphocytes, Thy-1 Antigens, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review